CHE
HealthcareChemed Corporation · Medical - Care Facilities · $6B
What is Chemed Corporation?
Chemed Corporation is a Cincinnati-based holding company operating two distinct businesses: VITAS Healthcare, one of the largest hospice care providers in the United States, and Roto-Rooter, a well-known plumbing and drain services brand.
Through VITAS, Chemed delivers hospice and palliative care to terminally ill patients via a network of physicians, nurses, social workers, and volunteers across the US. Through Roto-Rooter, it provides plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers via company-owned branches, independent contractors, and franchisees. This dual-segment structure gives Chemed exposure to both the growing end-of-life care market and the steady demand for essential home services.
Chemed was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
- Hospice and palliative care services (VITAS Healthcare)
- Plumbing and drain cleaning services (Roto-Rooter)
- Water restoration and excavation services
- Franchise and independent contractor service network
- Home health aide and social worker care coordination
Is CHE a Good Stock to Buy?
UQS Score rates CHE as Good overall, reflecting a balanced profile across its five analytical pillars.
Chemed's Quality and Risk pillars both register as Good, suggesting the business generates reliable results while maintaining a manageable financial risk profile. Valuation also comes in as Good, meaning the stock does not appear significantly stretched relative to its fundamentals — a notable trait in the healthcare services space.
Growth is the standout weakness in CHE's profile, rated Weak, which signals that near-term expansion may be limited. The Moat pillar sits at Neutral, indicating the company's competitive advantages are present but not dominant.
Pro members can view the exact pillar breakdown and full financial metrics behind CHE's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CHE pay dividends?
Yes — Chemed Corporation pays a dividend.
Chemed pays a regular dividend, which is relatively uncommon among healthcare services companies of its size. The dividend reflects the company's ability to generate consistent cash flows across both the VITAS and Roto-Rooter segments. Income-oriented investors may find CHE's dividend cadence appealing, though the yield sits in a modest range typical of diversified healthcare operators.
When does CHE report earnings?
Chemed Corporation reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's dual-segment structure means quarterly results are shaped by both hospice patient census trends in VITAS and seasonal plumbing demand in Roto-Rooter. Investors typically watch both segments for signs of volume growth and margin stability.
For the most recent quarter's results and guidance, visit Chemed's investor relations page directly.
CHE Price History
-22.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Chemed Corporation?
Based on Chemed Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CHE Long-term Outlook
CHE's Growth pillar rating of Weak suggests the near-term revenue trajectory may be modest relative to broader healthcare sector peers. However, the Good Risk rating indicates the business is not exposed to outsized financial or operational hazards. The combination of a stable hospice care model — supported by demographic tailwinds from an aging US population — and a resilient essential-services brand in Roto-Rooter provides a degree of fundamental durability even in slower-growth environments.
Growth drivers
- Aging US population increasing demand for hospice and palliative care
- Roto-Rooter's essential-services model providing recession-resilient revenue
- Potential for VITAS network expansion into underserved geographies
Key risks
- Regulatory and reimbursement changes in Medicare hospice programs
- Limited near-term growth momentum as reflected in the Weak Growth pillar
- Labor cost pressures across both nursing and skilled trades workforces
CHE vs Peers
Chemed operates in a niche corner of healthcare services, but several companies compete for similar patient populations or investor attention.
Option Care Health focuses on home and alternate-site infusion therapy rather than hospice, targeting a different but overlapping patient population.
Brookdale operates senior living communities, competing with VITAS for end-of-life care patients but through a facility-based rather than home-based model.
DaVita specializes in kidney care and dialysis services, representing a distinct chronic-disease model within the broader home and outpatient healthcare services space.
Frequently Asked Questions
What does Chemed Corporation do?
Chemed operates two businesses: VITAS Healthcare, which provides hospice and palliative care to terminally ill patients across the United States, and Roto-Rooter, which offers plumbing, drain cleaning, and water restoration services to residential and commercial customers. The combination makes Chemed one of the more unusual diversified companies in the healthcare sector.
Does CHE pay dividends?
Yes, Chemed pays a regular dividend. The company's ability to generate consistent cash flows from both its hospice and plumbing segments supports this payout. Investors seeking income alongside a healthcare-services exposure may find the dividend cadence worth examining, though yield levels are modest relative to pure-play income stocks.
When does CHE report earnings?
Chemed reports on a standard quarterly schedule. Results typically reflect trends in VITAS patient census and Roto-Rooter seasonal demand. For the exact release date of the next earnings report, check Chemed's official investor relations page, as our data source does not cover forward-looking calendar dates.
Is CHE a good stock to buy?
UQS Score rates CHE as Good overall. The Quality, Risk, and Valuation pillars are all rated Good, while Growth is Weak and Moat is Neutral. Whether that profile suits your portfolio depends on your goals — Pro members can access the complete pillar breakdown and underlying financial metrics to make a more informed assessment.
Is CHE overvalued?
CHE's Valuation pillar is rated Good, suggesting the stock is not obviously overpriced relative to its fundamentals at the time of scoring. That said, valuation is dynamic and should be reviewed alongside the full UQS analysis available to Pro members for the most current picture.
How does CHE compare to its competitors?
Chemed's closest peers include Option Care Health, Brookdale Senior Living, and DaVita — each operating in adjacent areas of healthcare services. CHE's dual-segment model, combining hospice care with essential home services, is relatively unique. The UQS platform scores each competitor separately, and Pro members can compare pillar-level ratings side by side.
What is CHE's market cap bracket?
Chemed Corporation is classified as a mid-cap company. This places it in a range that typically offers more stability than small-cap names while retaining some growth optionality compared to large-cap healthcare conglomerates.
Who founded Chemed Corporation?
Chemed was incorporated in 1970 and is headquartered in Cincinnati, Ohio. Detailed founding history, including key executives involved in the company's formation, is widely available through Chemed's official corporate history and public filings.
Is CHE a long-term quality stock?
As a long-term quality indicator, CHE's Good overall UQS Score reflects a business with reliable fundamentals and manageable risk. The Weak Growth pillar is a consideration for investors prioritizing expansion, but the stable hospice care model and essential-services brand provide a degree of durability over time. Pro members can dig into the full analysis to assess long-term fit.
What is the main competitive advantage of Chemed?
Chemed's Moat pillar is rated Neutral, suggesting its competitive advantages are real but not dominant. VITAS benefits from regulatory complexity and established referral networks in hospice care, while Roto-Rooter carries strong brand recognition built over decades in the plumbing services market. Together, these create a degree of defensibility without constituting a wide economic moat.
What sector does CHE belong to?
Chemed is classified in the Healthcare sector, primarily due to the VITAS hospice segment. However, the Roto-Rooter segment adds an element of consumer and commercial services exposure, making CHE somewhat atypical compared to pure-play healthcare stocks. Investors should consider both segments when evaluating sector fit.
Unlock Full CHE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View CHE's exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics behind the Quality score
- ✓Compare CHE side-by-side with OPCH, BKD, and DVA
- ✓See Valuation and Risk breakdowns updated each quarter
- ✓Filter mid-cap healthcare stocks by UQS pillar strength
- ✓Get the full analyst-grade view in one place
Pro Analysis
CHE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 58.0 | 76.0 | 42.0 | 38.9 | 67.7 | 70.7 | -0.1 |
| May 19, 2026 | 58.1 | 76.0 | 42.0 | 38.9 | 67.7 | 71.0 | 0.0 |
| May 16, 2026 | 58.1 | 76.0 | 42.0 | 38.9 | 67.7 | 71.4 | -0.1 |
| May 15, 2026 | 58.2 | 76.0 | 42.0 | 38.9 | 67.7 | 71.9 | 0.0 |
| May 14, 2026 | 58.2 | 76.0 | 42.0 | 38.9 | 67.7 | 72.1 | -0.1 |
| May 13, 2026 | 58.3 | 76.0 | 42.0 | 38.9 | 67.7 | 72.4 | 0.0 |
| May 12, 2026 | 58.3 | 76.0 | 42.0 | 38.9 | 67.7 | 72.3 | +0.1 |
| May 11, 2026 | 58.2 | 76.0 | 42.0 | 38.9 | 67.7 | 72.1 | +1.9 |
| May 10, 2026 | 56.3 | 71.1 | 42.0 | 38.9 | 67.7 | 67.0 | 0.0 |
| May 8, 2026 | 56.3 | 71.1 | 42.0 | 38.9 | 67.7 | 67.4 | -2.2 |
CHE — Pillar Breakdown
Quality
— 76.0/100 (25%)Chemed Corporation demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 38.9/100 (20%)Chemed Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 67.7/100 (15%)Chemed Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 72.7/100 (15%)Chemed Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Chemed Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CHE.
Score Composition
Financial Data
More Stock Analysis
How is the CHE UQS Score Calculated?
The UQS (Unified Quality Score) for Chemed Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Chemed Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Chemed Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.